-
Stock Abbreviation: Qianhong Pharmaceutical Stock Code: 002550 Changzhou Qianhong Biopharma Co., Ltd. (No. 518, Yunhe Road, Xinbei District, Changzhou) Reply to the Inquiry Letter Regarding Changzhou Qianhong Biopharma Co., Ltd.'s Application for Issuing Convertible Bonds to Unspecified Objects (Revised Draft) Sponsoring Institution (Lead Underwriter) (No. 401, Building B7, Qianhai Shenzhen-Hong Kong Fund Town, 128 Guiwan 5th Road, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone) May 2026
-
Shenzhen Stock Exchange: We have received your inquiry letter dated February 12, 2026, regarding Changzhou Qianhong Biopharma Co., Ltd.'s application for issuing convertible bonds to unspecified objects (Inquiry Letter [2026] No. 120011) (hereinafter referred to as "Inquiry Letter"). Changzhou Qianhong Biopharma Co., Ltd. (hereinafter referred to as "Qianhong Pharmaceutical," "the Company," "the Issuer") has conducted a thorough review of the issues listed in the Inquiry Letter with the sponsoring institution Huatai United Securities Co., Ltd. (hereinafter referred to as "the Sponsoring Institution," "Huatai United"), the issuer's lawyer Beijing Guofeng Law Firm (hereinafter referred to as "the Issuer's Lawyer," "Guofeng"), and the reporting accountant Tianye Accounting Firm (Special General Partnership) (hereinafter referred to as "the Accountant," "Tianye"). We now provide the following responses for your review.
Note: 1. Unless otherwise specified, the abbreviations or terms in this reply have the same meanings as those in the "Prospectus for Changzhou Qianhong Biopharma Co., Ltd. Issuing Convertible Bonds to Unspecified Objects and Listing on the Main Board." 2. If there are discrepancies between the total amounts and the sum of individual items in this reply, they are due to rounding. 3. The font in this reply indicates the following meanings: Issues listed in the Inquiry Letter are in regular font (not bold), responses to the issues listed in the Inquiry Letter are in Song font (not bold), and modifications or supplements to the application documents and this reply are in italicized bold font.